Diabetes Care 24:875-880, 2001
© 2001 by the American Diabetes Association, Inc.
Emerging Treatments and Technologies Original Article |
Long-Term Oral L-Arginine Administration Improves Peripheral and Hepatic Insulin Sensitivity in Type 2 Diabetic Patients
PierMarco Piatti, MD1,
Lucilla D. Monti, MD2,
Gianpietro Valsecchi, PHD2,
Fulvio Magni, MD3,
Emanuela Setola, MD1,
Federica Marchesi, MD2,
Marzia Galli-Kienle, MD4,
Guido Pozza, MD5 and
K. George M.M. Alberti, FRCP5
1 Metabolic Diseases Unit
2 Medicine I Division
3 Mass-Spectrometry Unit Cattedra di Clinica Medica Generale e Terapia Medica, Università Vita-Salute, IRCCS H. San Raffaele
4 University of Milano-Bicocca, Faculty of Medicine, Milan, Italy
5 Department of Diabetes and Metabolism, School of Clinical Medical Sciences, University of Newcastle, Newcastle upon Tyne, U.K.
OBJECTIVEThe aim of this study was to evaluate whether long-term administration of L-arginine acting through a normalization of NO/cyclic-guanosine-3',5'-cyclic monophosphate (cGMP) pathway was able to ameliorate peripheral and hepatic insulin sensitivity in 12 lean type 2 diabetic patients.
RESEARCH DESIGN AND METHODSA double-blind study was performed for 3 months. In the first month, patients were treated with their usual diet. Then they were randomly allocated into two groups. In group 1, patients were treated with diet plus placebo (orally three times per day) for 2 months. In group 2 patients were treated for 1 month with diet plus placebo (orally, three times per day) and then for 1 month with diet plus L-arginine (3 g three times per day). At the end of the first and the second month of therapy, patients underwent a euglycemic-hyperinsulinemic clamp combined with [6,6-2H2]glucose infusion. A total of 10 normal subjects underwent the same test as control subjects.
RESULTSIn group 1, no changes in basal cGMP levels, systolic blood pressure, forearm blood flow, glucose disposal, and endogenous glucose production were observed throughout. In group 2, L-arginine normalized basal cGMP levels and significantly increased forearm blood flow by 36% and glucose disposal during the clamp by 34%, whereas it decreased systolic blood pressure and endogenous glucose production by 14 and 29%, respectively. However, compared with normal subjects, L-arginine treatment was not able to completely overcome the defect in glucose disposal.
CONCLUSIONSL-Arginine treatment significantly improves but does not completely normalize peripheral and hepatic insulin sensitivity in type 2 diabetic patients.
Abbreviations: cGMP, cyclic-guanosine-3',5'-cyclic monophosphate CV, coefficient of variation NO, nitric oxide NOS, NO synthase

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
V. Ouellet, J. Marois, S. J. Weisnagel, and H. Jacques
Dietary Cod Protein Improves Insulin Sensitivity in Insulin-Resistant Men and Women: A randomized controlled trial
Diabetes Care,
November 1, 2007;
30(11):
2816 - 2821.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Krzyzanowska, F. Mittermayer, M. Wolzt, and G. Schernthaner
Asymmetric Dimethylarginine Predicts Cardiovascular Events in Patients With Type 2 Diabetes
Diabetes Care,
July 1, 2007;
30(7):
1834 - 1839.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Lucotti, E. Setola, L. D. Monti, E. Galluccio, S. Costa, E. P. Sandoli, I. Fermo, G. Rabaiotti, R. Gatti, and P. Piatti
Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients
Am J Physiol Endocrinol Metab,
November 1, 2006;
291(5):
E906 - E912.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. D. Monti, E. Setola, G. Fragasso, R. P. Camisasca, P. Lucotti, E. Galluccio, A. Origgi, A. Margonato, and P. Piatti
Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy
Am J Physiol Endocrinol Metab,
January 1, 2006;
290(1):
E54 - E59.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. K. McConell, N. N. Huynh, R. S. Lee-Young, B. J. Canny, and G. D. Wadley
L-Arginine infusion increases glucose clearance during prolonged exercise in humans
Am J Physiol Endocrinol Metab,
January 1, 2006;
290(1):
E60 - E66.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Nystrom, A. Nygren, and A. Sjoholm
Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease
Am J Physiol Endocrinol Metab,
November 1, 2004;
287(5):
E919 - E925.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Wilmore
Enteral and Parenteral Arginine Supplementation to Improve Medical Outcomes in Hospitalized Patients
J. Nutr.,
October 1, 2004;
134(10):
2863S - 2867S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. D. Monti, C. Landoni, E. Setola, E. Galluccio, P. Lucotti, E. P. Sandoli, A. Origgi, G. Lucignani, P. Piatti, and F. Fazio
Myocardial insulin resistance associated with chronic hypertriglyceridemia and increased FFA levels in Type 2 diabetic patients
Am J Physiol Heart Circ Physiol,
September 1, 2004;
287(3):
H1225 - H1231.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C Gannon, J. A Nuttall, and F. Q Nuttall
Oral arginine does not stimulate an increase in insulin concentration but delays glucose disposal
Am. J. Clinical Nutrition,
November 1, 2002;
76(5):
1016 - 1022.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. T. Huynh and J. A. Tayek
Oral Arginine Reduces Systemic Blood Pressure in Type 2 Diabetes: Its Potential Role in Nitric Oxide Generation
J. Am. Coll. Nutr.,
October 1, 2002;
21(5):
422 - 427.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Diabetes Association.
|
|
| |
|